| pubmed-article:15610250 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15610250 | lifeskim:mentions | umls-concept:C0022680 | lld:lifeskim |
| pubmed-article:15610250 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15610250 | lifeskim:mentions | umls-concept:C0449258 | lld:lifeskim |
| pubmed-article:15610250 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:15610250 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:15610250 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15610250 | pubmed:dateCreated | 2004-12-21 | lld:pubmed |
| pubmed-article:15610250 | pubmed:abstractText | It is not known whether angiotensin-converting-enzyme (ACE) inhibitors slow the progression of polycystic kidney disease (PKD). We performed a patient-level meta-analysis to compare the effect of antihypertensive regimens, including ACE inhibitors, to those without ACE inhibitors (controls) on kidney disease progression in patients with PKD. | lld:pubmed |
| pubmed-article:15610250 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15610250 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15610250 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15610250 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15610250 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15610250 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15610250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15610250 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15610250 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:15610250 | pubmed:issn | 0085-2538 | lld:pubmed |
| pubmed-article:15610250 | pubmed:author | pubmed-author:LeveyAndrew... | lld:pubmed |
| pubmed-article:15610250 | pubmed:author | pubmed-author:SchmidChristo... | lld:pubmed |
| pubmed-article:15610250 | pubmed:author | pubmed-author:KamperAnne-Li... | lld:pubmed |
| pubmed-article:15610250 | pubmed:author | pubmed-author:StarkPaul CPC | lld:pubmed |
| pubmed-article:15610250 | pubmed:author | pubmed-author:JafarTazeen... | lld:pubmed |
| pubmed-article:15610250 | pubmed:author | pubmed-author:StrandgaardSv... | lld:pubmed |
| pubmed-article:15610250 | pubmed:author | pubmed-author:MaschioGiusep... | lld:pubmed |
| pubmed-article:15610250 | pubmed:author | pubmed-author:PerroneRonald... | lld:pubmed |
| pubmed-article:15610250 | pubmed:author | pubmed-author:BeckerGavinG | lld:pubmed |
| pubmed-article:15610250 | pubmed:author | pubmed-author:ACE... | lld:pubmed |
| pubmed-article:15610250 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15610250 | pubmed:volume | 67 | lld:pubmed |
| pubmed-article:15610250 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15610250 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15610250 | pubmed:pagination | 265-71 | lld:pubmed |
| pubmed-article:15610250 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:15610250 | pubmed:meshHeading | pubmed-meshheading:15610250... | lld:pubmed |
| pubmed-article:15610250 | pubmed:meshHeading | pubmed-meshheading:15610250... | lld:pubmed |
| pubmed-article:15610250 | pubmed:meshHeading | pubmed-meshheading:15610250... | lld:pubmed |
| pubmed-article:15610250 | pubmed:meshHeading | pubmed-meshheading:15610250... | lld:pubmed |
| pubmed-article:15610250 | pubmed:meshHeading | pubmed-meshheading:15610250... | lld:pubmed |
| pubmed-article:15610250 | pubmed:meshHeading | pubmed-meshheading:15610250... | lld:pubmed |
| pubmed-article:15610250 | pubmed:meshHeading | pubmed-meshheading:15610250... | lld:pubmed |
| pubmed-article:15610250 | pubmed:meshHeading | pubmed-meshheading:15610250... | lld:pubmed |
| pubmed-article:15610250 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15610250 | pubmed:articleTitle | The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. | lld:pubmed |
| pubmed-article:15610250 | pubmed:affiliation | Division of Nephrology, New England Medical Center, Boston, Massachusetts, USA. tazeen.jafar@aku.edu | lld:pubmed |
| pubmed-article:15610250 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15610250 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:15610250 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15610250 | pubmed:publicationType | Meta-Analysis | lld:pubmed |
| pubmed-article:15610250 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15610250 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15610250 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15610250 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15610250 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15610250 | lld:pubmed |
